ABSTRACT
The discovery and SAR of a new series of substituted amino propanamide renin inhibitors are herein described. This work has led to the preparation of compounds with in vitro and in vivo profiles suitable for further development. Specifically, challenges pertaining to oral bioavailability, covalent binding and time-dependent CYP 3A4 inhibition were overcome thereby culminating in the identification of compound 50 as an optimized renin inhibitor with good efficacy in the hypertensive double-transgenic rat model.
Subject(s)
Antihypertensive Agents/chemistry , Antihypertensive Agents/therapeutic use , Hypertension/drug therapy , Renin/antagonists & inhibitors , Renin/metabolism , Animals , Antihypertensive Agents/pharmacology , Blood Pressure/drug effects , Crystallography, X-Ray , Dogs , Humans , Models, Molecular , Protein Binding , Rats , Rats, Sprague-Dawley , Renin/chemistry , Structure-Activity RelationshipABSTRACT
New classes of de novo designed renin inhibitors are reported. Some of these compounds display excellent in vitro and in vivo activities toward human renin in a TGR model. The synthesis of these new types of mono- and bicyclic scaffolds are reported, and properties of selected compounds discussed.
